(29 days)
Not Found
No
The device description focuses on the physical structure and materials of a vena cava filter. There is no mention of software, algorithms, or any technology that would suggest the use of AI or ML. The performance study described is a clinical trial evaluating the physical device's safety and efficacy.
Yes
The device is indicated for the prevention and treatment of pulmonary embolism, which is a medical condition. It directly intervenes to address a health issue by physically preventing emboli from reaching the lungs.
No
The device is a vena cava filter, which is an implantable medical device designed to prevent pulmonary embolisms. Its intended use is to physically filter blood and capture emboli, not to diagnose medical conditions or provide diagnostic information.
No
The device description clearly describes a physical implantable device made of stainless steel with legs and hooks, which is a hardware component, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is the prevention of recurrent pulmonary embolism by physically filtering the vena cava. This is a therapeutic intervention performed in vivo (within the body).
- Device Description: The device is a physical filter made of stainless steel, designed to be implanted in the vena cava. This is a medical device, not a diagnostic tool that analyzes samples in vitro (outside the body).
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.), using reagents, or providing diagnostic information based on laboratory tests.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
The ALN Optional Vena Cava Filter with Hook and without Hook are indicated for the prevention of recurrent pulmonary embolism via placement in the vena cava in the following situations:
-
Pulmonary thromboembolism when anticoagulants are contraindicated,
-
Failure of anticoagulant therapy in thromboembolic diseases,
-
Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced; and
-
Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated.
ALN Optional Vena Cava Filters with Hook and without Hook, may be retrieved with the ALN Extraction and /or Repositioning Kits according to the Instructions For Use of these devices.
The ALN Optional Vena Cava Filter with Hook may be also retrieved with a standard GooseNeck Snare according to the the Instructions For Use of this medical device.
Product codes (comma separated list FDA assigned to the subject device)
DTK
Device Description
The ALN Optional Vena Cava Filter is a conical-shaped structure made of 316LVM stainless steel and consisting of 9 legs (i.e., 9 filtering elements). The 6 shortest legs (i.e., anchoring legs) are ended with distal hooks and each leg has a different length to avoid intertwining when the filter is introduced into the sheath or released in the vessel. The 3 longest legs (i.e., centering legs) have no hooks and serve to line up the vena cava axis. The loop at the end of the longest one helps to push the filter during its implantation through the femoral vascular approach. All 9 legs are equally involved in capturing and breaking an embolus. The ALN Optional Vena Cava Filter is about 55 mm high and is suitable for vena cava diameters up to 32 mm. The implantation approaches may be jugular, brachial or femoral. The ALN Optional Vena Cava Filter with a Hook is the same ALN Optional Vena Cava Filter with an additional 4mm retrieval hook on the apex of the device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
vena cava
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
PRESERVE is an FDA-directed multicenter, prospective, open-label, non-randomized trial that studied the safety and efficacy of IVC filters from six manufacturers, including ALN. The study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3375 Cardiovascular intravascular filter.
(a)
Identification. A cardiovascular intravascular filter is an implant that is placed in the inferior vena cava for the purpose of preventing pulmonary thromboemboli (blood clots generated in the lower limbs and broken loose into the blood stream) from flowing into the right side of the heart and the pulmonary circulation.(b)
Classification. Class II. The special controls for this device are:(1) “Use of International Standards Organization's ISO 10993 ‘Biological Evaluation of Medical Devices Part I: Evaluation and Testing,’ ” and
(2) FDA's:
(i) “510(k) Sterility Review Guidance and Revision of 2/12/90 (K90-1)” and
(ii) “Guidance for Cardiovascular Intravascular Filter 510(k) Submissions.”
0
Image /page/0/Picture/0 description: The image contains the logos of the U.S. Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, featuring a stylized symbol. To the right is the FDA logo, with the acronym "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" and "ADMINISTRATION" in blue text.
June 26, 2024
Aln S.a.r.1. Alain Nigon Managing Director 589 chemin du Niel Bormes les Mimosas, 83230 France
Re: K241507
Trade/Device Name: ALN Optional Vena Cava Filter (FB.010500, FF.010995, FJ.120096, FB.HOOK, FF.HOOK, FJ.HOOK) Regulation Number: 21 CFR 870.3375 Regulation Name: Cardiovascular Intravascular Filter Regulatory Class: Class II Product Code: DTK Dated: April 22, 2024 Received: May 28, 2024
Dear Nigon Alain:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Ariel G. Ash-
shakoor -S
Digitally signed by Ariel G. Ashshakoor -S Date: 2024.06.26 11:08:56 -04'00"
For
Gregory O'Connell Assistant Director DHT2C: Division of Coronary and Peripheral Intervention Devices OHT2: Office of Cardiovascular Devices
2
Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K241507
Device Name
ALN Optional Vena Cava Filter (FB.010500, FF.010995, FJ.120096, FB.HOOK, FF.HOOK, FJ.HOOK)
Indications for Use (Describe)
The ALN Optional Vena Cava Filter with Hook and without Hook are indicated for the prevention of recurrent pulmonary embolism via placement in the vena cava in the following situations:
-
Pulmonary thromboembolism when anticoagulants are contraindicated,
-
Failure of anticoagulant therapy in thromboembolic diseases,
-
Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced; and
-
Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated.
ALN Optional Vena Cava Filters with Hook and without Hook, may be retrieved with the ALN Extraction and /or Repositioning Kits according to the Instructions For Use of these devices.
The ALN Optional Vena Cava Filter with Hook may be also retrieved with a standard GooseNeck Snare according to the the Instructions For Use of this medical device.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Submitter
| 510(k) Submitter | ALN S.A.R.L.
Mr. Alain NIGON
589 Chemin du Niel
83230 BORMES LES MIMOSAS
FRANCE
Phone: +33 4 94 01 05 01
Fax: +33 4 94 01 09 01
alain.nigon@aln2b.com |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact | ALN S.A.R.L.
Mrs. Séverine JOLY
ALN S.A.R.L.
Phone: +33 4 94 01 05 01
Fax: +33 4 94 01 09 01
severine.joly@aln2b.com |
| Date Prepared | June 25, 2024 |
| Device | |
| Trade Name of the Device | ALN Optional Vena Cava Filter (FB.010500, FF.010995, FJ.120096, FB.HOOK, FF.HOOK, FJ.HOOK) |
| Common Name of the Device | Vena Cava Filter |
| Classification Name | Cardiovascular Intravascular Filter (CFR 870.3375) |
| Product code | DTK |
| Regulatory Class | II |
| Device Panel | Cardiovascular |
5
Device Description
The device is unchanged in comparison to the predicate device.
The ALN Optional Vena Cava Filter is a conical-shaped structure made of 316LVM stainless steel and consisting of 9 legs (i.e., 9 filtering elements). The 6 shortest legs (i.e., anchoring legs) are ended with distal hooks and each leg has a different length to avoid intertwining when the filter is introduced into the sheath or released in the vessel. The 3 longest legs (i.e., centering legs) have no hooks and serve to line up the vena cava axis. The loop at the end of the longest one helps to push the filter during its implantation through the femoral vascular approach. All 9 legs are equally involved in capturing and breaking an embolus. The ALN Optional Vena Cava Filter is about 55 mm high and is suitable for vena cava diameters up to 32 mm. The implantation approaches may be jugular, brachial or femoral. The ALN Optional Vena Cava Filter with a Hook is the same ALN Optional Vena Cava Filter with an additional 4mm retrieval hook on the apex of the device.
Intended Use and Indications for Use
The intended use and the indications for Use are unchanged in comparison to the predicate device.
The ALN Optional Vena Cava Filter with Hook and without Hook are indicated for the prevention of recurrent pulmonary embolism via placement in the vena cava in the following situations:
-
Pulmonary thromboembolism when anticoagulants are contraindicated,
-
Failure of anticoagulant therapy in thromboembolic diseases,
-
Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced; and
-
Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated.
ALN Optional Vena Cava Filters with Hook and without Hook, may be retrieved with the ALN Extraction and/or Repositioning Kits according to the Instructions For Use of these devices.
The ALN Optional Vena Cava Filter with Hook may be also retrieved with a standard GooseNeck Snare according to the Instructions For Use of this medical device.
Predicate Device for equivalence
The legally marketed device to which ALN S.A.R.L. is claiming equivalence is ALN Optional Vena Cava Filter:
| Trade Name | ALN Optional Vena Cava Filter and ALN Extraction and/or Repositioning Kit |
|---|---|
| 510(k) Number | K163699 |
| Common Name | Vena Cava Filter and Extraction Kit |
| Classification Name | Cardiovascular Intravascular filter (870.3375) |
| Product Code | DTK |
| Regulatory Class | II |
| Device Panel | Cardiovascular |
Important note: the predicate device ALN Optional Vena Cava Filter was FDA Cleared together with ALN Extraction and/or Repositioning Kit, under the trade name "ALN Optional Vena Cava Filter and ALN Extraction and/or Repositioning Kit". The ALN Extraction and/or Repositioning Kit has been designed for the retrieval of an implanted predicate device ALN Optional Vena Cava Filter. This device modification concerns labeling changes only
6
ALN S.A.R.L - 510(k) summary - K241507
for the ALN Optional Vena Cava Filter. The labeling for the Extraction and/or Repositioning kit, remains unchanged.
Technological Characteristics
The technological characteristics are unchanged in comparison to the predicate device.
- -Technological principle: the technological principle is unchanged in comparison to the predicate device. The mechanical trapping of blood clots. It is based on the filtering legs constituting the conical-shaped filter and the compression movement in the inferior vena cava, preventing them from reaching the heart and lungs, and reducing the risk of pulmonary embolism.
- -Design: The design is unchanged in comparison to the predicate device. The ALN Optional Vena Cava Filter is a conical-shaped structure consisting of 9 legs at two different levels: an upper level for anchoring (6 shorter legs) and a lower level for centering (3 longer legs). The legs are crimped inside the filter apex. The distal tip of the anchoring legs is curved in a hook shape allowing an active anchorage. Two centering legs with flaked to reduce traumatic risk on the vena wall. One centering leg with a loop allow to push the filter during femoral implantation. The implantation kit includes: the ALN filter in its filter-holder, an introduction system (dilator, introducer sheath, pushing catheter), a puncture needle and a J-guidewire.
- -Raw Materials: The raw material is unchanged in comparison to the predicate device. The ALN Optional Vena Cava Filter is made of 316 LVM stainless-steel.
- -Manufacturing process: the manufacturing process is unchanged in comparison to the predicate device .
- -Packaging and sterilization process: the packaging and sterilization processes are unchanged in comparison to the predicate device.
Labeling
The product labels and the patient card are unchanged in comparison to the predicate device.
The Instructions for Use are updated in comparison to the predicate device.
The PRESERVE Study summary is included in the Instruction for Use of each model of ALN Optional Vena Cava Filter, at the FDA's request.
PRESERVE is an FDA-directed multicenter, prospective, open-label, non-randomized trial that studied the safety and efficacy of IVC filters from six manufacturers, including ALN. The study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE).
Substantial Equivalence
The design, material, components, fundamental technology, intended use and indications for use are unchanged in comparison to the predicate device.
The reason for submitting this Special 510(k) notification is about a labeling change, requested by the FDA to all manufacturer following the PRESERVE study outcomes: inclusion of new clinical data (summary of the PRESERVE study) in the Instruction for Use of the ALN Optional Vena Cava Filter.
7
Conclusion
The comparison of design, material, components, technological characteristics, intended use, and indications for use demonstrate that the modification to the labeling does not raise new questions of safety and effectiveness and supports substantial equivalence of the subject device to the predicate device.